Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method of reducing neuronal cell damage

A neuron cell, monoamine neurotransmitter technology, applied in the direction of extracellular fluid diseases, nervous system diseases, botany equipment and methods, etc., can solve the problem that amphetamine will not improve recovery and other problems

Inactive Publication Date: 2009-08-26
UNIVERSITY OF MONTANA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prior art also teaches that amphetamines do not improve recovery after certain types of damage, including damage to the substantia nigra (Mintz and Tomer 1986)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of reducing neuronal cell damage
  • Method of reducing neuronal cell damage
  • Method of reducing neuronal cell damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0051] The neuroprotective efficacy of amphetamines after transient ischemic injury has not been previously investigated. In this study, methamphetamine (MA) was evaluated using in vitro and in vivo models of transient cerebral ischemia. For the in vitro model, rat hippocampal slice cultures were challenged under hypoxia and glucose deficiency. In a second series of experiments, the in vivo neuroprotective efficacy of MA was investigated using a combination of a 5-minute 2-VO occlusion gerbil model and behavioral testing. During this study it was surprisingly found and demonstrated that administration of MA within 16 hours after transient cerebral ischemia is indeed neuroprotective, reducing neuronal cell damage, including death.

[0052] Materials and methods

[0053] 1.1 Animals

[0054] All experimental animal manipulations were approved by the University Institutional AnimalCare and Use Committee. Twenty-eight adult male Mongolian gerbils (gerbils) weighing 60-80 gm we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and / or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and / or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.

Description

[0001] Information about the application [0002] This application claims the benefit of US Provisional Application 60 / 839,974, filed August 23, 2006, the contents of which are expressly incorporated herein by reference in their entirety. technical field [0003] The present invention relates to a method for alleviating neuron cell damage including cell death caused by transient cerebral hypoxia and / or ischemia. The method comprises the steps of: diagnosing a patient with a transient cerebral hypoxic and / or ischemic condition; and administering to the patient a neuroprotective amount of the agent within 16 hours of onset of the condition. The agent is preferably selected from: central nervous system stimulants (CNSS), monoamine neurotransmitters, monoamine oxidase inhibitors (MAOI), tricyclic antidepressants (TCAs) or combinations thereof. Preferred agents include amphetamine, methamphetamine (MA), methylphenidate, methylenedioxymethamphetamine, or combinations thereof. Ba...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01N43/42A61K31/44
CPCA61K31/4458A61K31/137A61K31/4045A61K31/135A61K31/445A61K45/06A61P25/00A61P25/28A61P27/02A61P7/04A61P9/02A61P9/10A61K2300/00A61K31/44
Inventor D·J·鲍尔森T·F·劳
Owner UNIVERSITY OF MONTANA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com